Tablets & Capsules

TC0520

Issue link: https://www.e-digitaleditions.com/i/1244583

Contents of this Issue

Navigation

Page 5 of 43

4 May 2020 Tablets & Capsules markets Pharmaceutical robots market to exceed $227 million by 2026 PUNE, India—The global phar- maceutical robots market is forecast to grow at a compound annual rate of 13.45 percent and will be worth $227.36 million by 2026, according to a report by to Data Bridge Mar- ket Research. Increasing consumer demand for personalized packaging and a rising awareness of robotic sys- tems in the pharmaceutical industry will drive market growth. The report identifies Kawasaki Heavy Industries, Fanuc, Kuka, Mitsubishi Electric, ABB Robotics, Denso, Seiko Epson, Marchesini, Universal Robots, Yas- kawa Electric, Shibuya, Krones, Rem- tec Automation, and Robert Bosch as major market players. Dietary supplement market to grow 7.8 percent annually through 2025 DALLAS, TX—The rising accep- tance of preventive management and a growing health awareness of weight management is expected to drive global dietary supplements market growth at a compound annual rate of 7.8 percent through 2025, according to a report by Adroit Market Research. Also, the grow- ing demand for microencapsulation in the pharmaceutical industry will spur dietary supplement manufac- turers to use capsule dosage forms over the forecast period. Some of the leading industry players include ADM, Abbott Laboratories, Pfizer, Arkopharma Laboratories Pharma- ceutiques, Carlyle, Amway, Glanbia Nutritionals, Bayer, Herbalife Inter- national, and GlaxoSmithKline. Continuous manufacturing to drive granulator market growth S E A T T L E , W A — T h e g l o b a l pharmaceutical granulators market is forecast to grow at a compound annual rate of 5.6 percent due to an increasing demand for oral dose medications, according to Coherent Market Insights. Advances in gran- ulator technology for continuous manufacturing are expected to drive market growth. Key market players identified in the report include L.B. Bohle, Alexanderwerk, GEA, Frewitt, Linxis, Spraying Systems, Syntegon Technology, Romaco, Gebrüder Lödige, and Glatt. Government initiatives will continue to spur continuous manufacturing growth LYON, France—The global phar- maceutical continuous manufactur- ing market is forecast to grow at a compound annual rate of 8.45 per- cent through 2028. Factors driving growth include the rising adoption of pharmaceutical continuous man- ufacturing systems, opportunities in emerging economies, and increas- ing government initiatives for the adoption of pharmaceutical con- tinuous manufacturing. The report identifies Coperion, Eli Lilly, GEA, Gebrüder Lödige, Glatt, Hosokawa Micron, Korsch, L.B. Bohle, Munson Machinery, Pfizer, Siemens, Syn- tegon, and Thermo Fisher Scientific as key market players. industry news FDA issues temporary policy for compounding certain drugs S I L V E R S P R I N G , M D — T h e FDA issued a guidance establish- ing a temporary policy allowing outsourcing facilities to compound certain human drugs during the COVID-19 pandemic to ensure treatment options are available for hospitalized patients with COVID- 19 when hospitals are experiencing drug shortages. For certain drugs, the agency will not take action against outsourcing facilities for compounding a drug that is essen- tially a copy of an approved drug, using a bulk drug substance that is not on the 503B bulks list, or not meeting current good manufac- turing practice requirements with regard to product stability testing and the establishment of an expi- ration date when certain circum- stances are present. FDA extends RWD funding application deadline S I L V E R S P R I N G , M D — T h e FDA has extended the deadline to June 5 to apply for funding for proj- ects that examine the use of real- world data (RWD) to generate real-world evidence (RWE) in regu- latory decision-making. Projects may focus on exploring and conducting innovative clinical trials; explaining ways to address challenges of using RWD in research studies; explor- ing innovative technologies; design- ing and conducting pilot projects; determining endpoints that RWD can capture; and evaluating reliabil- ity considerations of RWD. FDA revises pandemic postmarketing adverse event guidance SILVER SPRING, MD—The FDA published a revised final guidance for industry on postmarketing adverse event reporting for drugs, biologics, medical devices, combination prod- ucts, and dietary supplements during a pandemic. The agency's approach is intended to help firms with report- ing responsibilities to focus their lim- ited resources on reporting medical products for the treatment or pre- vention of the pathogen causing the pandemic, among other reports. This revised guidance replaces the 2012 guidance "Postmarketing Adverse Event Reporting for Medical Prod- u cts an d D ietary S u p p lem en ts During an Influenza Pandemic," to clarify the guidance is applicable to any pandemic, including the current COVID-19 pandemic. Purdue grants early graduation to pharmacy students WEST LAFAYETTE, IN—Pur- due University's College of Phar- macy granted early graduation to 144 students to help fill the poten- tial shortage of pharmacists during the COVID-19 pandemic. The move made Purdue one of the first colleges in the nation to certify its entire class of eligible pharmacy students. By granting certification to the school's fourth-year students, all of whom met the requirements

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC0520